Log In
Print this Print this

Retavase, Reteplase (rPA)

  Manage Alerts
Collapse Summary General Information
Company Chiesi Farmaceutici S.p.A.
DescriptionRecombinant plasminogen activator modified to retain activity longer, permitting administration in two single injections
Molecular Target Plasminogen
Mechanism of ActionAnti-thrombotic/thrombolytic
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationMyocardial infarction (MI)
Indication DetailsTreat acute myocardial infarction (AMI); Treat myocardial infarction ((MI) heart attack); Treat myocardial infarction (MI) in combination with ReoPro abciximab platelet antagonist monoclonal antibody
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today